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Medullary norepinephrine neurons modulate local oxygen
concentrations in the bed nucleus of the stria terminalis
Elizabeth S Bucher, Megan E Fox, Laura Kim, Douglas C Kirkpatrick, Nathan T Rodeberg, Anna M Belle and R Mark Wightman
Neurovascular coupling is understood to be the underlying mechanism of functional hyperemia, but the actions of the
neurotransmitters involved are not well characterized. Here we investigate the local role of the neurotransmitter norepinephrine in
the ventral bed nucleus of the stria terminalis (vBNST) of the anesthetized rat by measuring O2, which is delivered during functional
hyperemia. Extracellular changes in norepinephrine and O2 were simultaneously monitored using fast-scan cyclic voltammetry.
Introduction of norepinephrine by electrical stimulation of the ventral noradrenergic bundle or by iontophoretic ejection induced
an initial increase in O2 levels followed by a brief dip below baseline. Supporting the role of a hyperemic response, the O2 increases
were absent in a brain slice containing the vBNST. Administration of selective pharmacological agents demonstrated that
both phases of this response involve b-adrenoceptor activation, where the delayed decrease in O2 is sensitive to both a- and
b-receptor subtypes. Selective lesioning of the locus coeruleus with the neurotoxin DSP-4 confirmed that these responses are
caused by the noradrenergic cells originating in the nucleus of the solitary tract and A1 cell groups. Overall, these results support
that non-coerulean norepinephrine release can mediate activity-induced O2 influx in a deep brain region.
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INTRODUCTION
The neurovascular unit, composed of neuronal, glial, and vascular
elements, serves to support brain function by matching O2-rich
blood flow with the metabolic demands of regional activity. It is
understood that the products of local neurotransmission trigger
this response, known as functional hyperemia; however, much
remains to be learned regarding the actions and mechanisms of
the chemical messengers involved.1 This information is crucial to
understanding disease pathologies that involve dysregulation of
cerebral blood flow (CBF)—including cerebral ischemia2 and many
forms of dementia3—as well as to interpreting data from brain
imaging techniques such as blood O2 level-dependent functional
magnetic resonance imaging.
The catecholamine norepinephrine is one major neurotrans-
mitter implicated in this hemodynamic process. Its neurons lie in
several nuclei, designated A1 to 7, scattered along the hindbrain
and brainstem. These cell populations diffusely project throughout
the brain and terminate primarily as non-junctional varicosities,4
allowing their activity to exert a broad field of influence. The
noradrenergic neurons of the locus coeruleus (LC, A6) are typically
associated with the neurovascular unit. These neurons provide the
majority of cortical noradrenergic input, and they terminate
proximal to both astrocytes and microvessels.5,6 The presence of
adrenoceptors on these neurovascular targets,7 which are
sensitive to LC denervation,5,8 provides further evidence that the
LC norepinephrine system is positioned to influence their
activities. Indeed, studies have established that noradrenergic
signaling can influence energy metabolism,9 vascular per-
meability,10 ionic fluctuations in astrocytes,11 as well as gluta-
mate signaling by modulation of its synthesis12 and uptake.13
Other reports have demonstrated that CBF responses coincide
with altered LC activity.10,14,15
Here we consider the vasoactivity of norepinephrine in a region
weakly innervated by the LC: the ventral bed nucleus of the stria
terminalis (vBNST). The vBNST is a structure of the extended
amygdala involved in the autonomic and behavioral responses to
stress.16 We targeted this deep brain region as it receives the
densest norepinephrine input in the brain.17 Its noradrenergic
innervation arises primarily from the nucleus of the solitary tract
(A2) and the A1 cell group through the ventral noradrenergic
bundle (VNB).18 These cell groups are located in the medulla
oblongata, and receive cardiovascular, respiratory, gastrointestinal,
and other visceral information from peripheral afferents. Although
these norepinephrine populations have not been formally
associated with cerebral hemodynamic function, their terminals
are associated with the perivascular space in regions such as the
paraventricular nucleus.19 In addition, non-specific chemical
stimulation of nucleus of the solitary tract neurons attenuates
CBF, and this effect is believed to be neurogenic in origin.20
In this study, norepinephrine concentrations were transiently
increased within the vBNST by electrical stimulation of the VNB
and by local application through iontophoresis. Fast-scan cyclic
voltammetry at a carbon fiber microelectrode was employed to
simultaneously detect norepinephrine transients and changes in
extracellular O2 with subsecond and micrometer resolution.
Extracellular O2 is a function of ongoing metabolism and local
blood flow. We found that surges of norepinephrine in the vBNST
are accompanied by an increase in O2 that is followed by a
transient decrease below baseline levels. This response is due to
the local actions of norepinephrine at its receptors and does not
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depend on LC functionality. In a brain slice that lacks CBF,
iontophoresis of norepinephrine had no effect on measured O2
concentrations whereas electrical stimulation caused O2 concen-
tration to decrease, supporting a role for functional hyperemia as
the origin of our in vivo results.
MATERIALS AND METHODS
Chemicals and Drugs
All chemicals and drugs were used as received from Sigma-Aldrich
(St Louis, MO, USA), unless otherwise noted.
Electrode Fabrication
Two electrode types were employed in this study. Experiments without
iontophoresis used single barrel carbon fiber microelectrodes.21 Each
electrode was cut under a light microscope to an exposed length of
100mm. For iontophoresis experiments, voltammetric recordings were
made with four-barrel probes.22 One barrel housed a carbon fiber
electrode while the other three barrels contained the desired solutions.
Fast-Scan Cyclic Voltammetry
Fast-scan cyclic voltammetry was computer controlled using a data
acquisition program (High Definition Cyclic Voltammetry, UNC-Chapel Hill,
NC, USA)23 programmed in LabVIEW (National Instruments, Austin, TX,
USA). A single PCIe-6363 card (National Instruments) generated the
voltammetric and stimulation waveforms and simultaneously collected
cyclic voltammograms. The voltammetric waveform was applied to the
carbon fiber microelectrode and its current response transduced through a
locally constructed UEI potentiostat (UNC Department of Chemistry
Electronics Design Facility).
Voltammetric recordings employed two waveforms. For electrode
placement, iontophoresis barrel priming, and post-experiment signal
verification, a triangular waveform designed specifically for catecholamine
detection was used. This waveform scanned between  0.4 and 1.3 V at
400 V/second.24 For combined measurements of O2 and norepinephrine,
the voltage ramp scanned at 400 V/second between 0.8 and  1.4 V with
a holding potential of 0 V.25 Before use of either waveform, the electrode
was conditioned with the voltage ramp for 15 minutes at 60 Hz and
15 minutes at 10 Hz. Recordings were made at a 10 Hz application
frequency.
Calibrations
Electrode responses to norepinephrine, O2, and 4-methylcatecholamine
were determined through an air-impermeable flow-injection analysis
system with glass syringes and PEEK tubing (Sigma-Aldrich). All standards
were prepared in Tris buffer (15 mmol/L Tris, 126 mmol/L NaCl, 2.5 mmol/L
KCl, 25 mmol/L NaHCO3, 2.4 mmol/L CaCl2, 1.2 mmol/L NaH2PO4, 1.2 mmol/
L MgCl2, 2.0 mmol/L Na2SO4 ) adjusted to pH 7.4 with NaOH. O2
calibrations employed a N2-purged solution, an air-saturated solution,
and an O2-saturated solution. Peak reduction currents were taken for O2
calibrations, while peak oxidation currents were used for the catechola-
mines. The average calibration factors were as follows: 16.4 nA/mmol/L
norepinephrine (þ 1.3 V waveform),  0.3 nA/mmol/L O2 and 8.9 nA/mmol/
L 4-methylcatechol (O2-sensitive waveform).
Voltammetric Data Presentation and Analysis
Fast-scan cyclic voltammetry data were processed through the High
Definition Cyclic Voltammetry analysis program. Each file was digitally
filtered (4th order low pass Bessel, 2 KHz cutoff) and background
subtracted from baseline currents. Data are presented as color plots, with
the waveform plotted along the ordinate and the acquisition time shown
along the abscissa. Currents are mapped in false color in a 3:  2 ratio.
Principal component regression, a multivariate chemometric algorithm,
was used to determine concentrations for data collected on the  0.4 V/
þ 1.3 V waveform.26
Unless otherwise indicated data are shown as mean±s.e.m. All n-values
represent number of animals. Data were considered statistically significant
when Po0.05.
Surgery
All animal procedures were approved by the Institutional Animal Care and
Use Committee of the University of North Carolina at Chapel Hill in
accordance with the Public Health Service policy on Humane Care and Use
of Laboratory Animals and the Amended Animal Welfare Act of 1985. Care
was taken to minimize the number of animals used in this study and their
suffering. Adult male Sprague–Dawley rats (300 to 400 g) were purchased
from Charles River (Wilmington, MA, USA). Animals were anesthetized with
urethane (1.5 g/kg) and placed in a stereotaxic frame (Kopf, Tujunga, CA,
USA). Surgical procedures were as described previously27 with anterior–
posterior, medial–lateral, and dorsal–ventral coordinates referenced from
bregma according to Paxinos and Watson (2007). A fresh carbon fiber
microelectrode was lowered into the vBNST (anterior–posterior þ 0.0 mm,
medial–lateral þ 1.2 mm, dorsal–ventral  7.0 to  7.8 mm), and an Ag/
AgCl reference was implanted in the contralateral hemisphere. A bipolar
stimulating electrode (Plastics One, West Lafayette, IN, USA) was placed in
the VNB (anterior–posterior  5.2 mm, medial–lateral þ 1.2 mm, dorsal–
ventral  8.0 to 8.6 mm) ipsilaterally to the recording electrode. Electrical
stimulations (10 to 80 biphasic pulses, 60 Hz, ±300mA, 2 milliseconds per
pulse) were delivered via an optically isolated stimulator (NL 800 A,
Neurolog, Digitimer, Hertfordshire, UK). The depths of the carbon fiber and
stimulating electrodes were adjusted to achieve maximal measured
norepinephrine release.
In Vitro Procedure
Brain slices containing the vBNST were prepared from Sprague–Dawley
rats (300 to 400 g) anesthetized with urethane (1.5 g/kg). Brains were
quickly removed after decapitation and submerged in ice-cold, oxyge-
nated (95% O2/5% CO2) bicarbonate buffer solution (87 mmol/L NaCl,
2.5 mmol/L KCl, 1.2 mmol/L NaH2PO4, 25 mmol/L NaHCO3, 7 mmol/L MgCl2,
0.5 mmol/L CaCl2, 75 mmol/L sucrose) adjusted to pH 7.4. A Vibroslice NVSL
Vibratome (World Precision Instruments, Sarasota, FL, USA) was used to cut
300mm coronal sections. Bed nucleus of the stria terminalis slices were
transferred to a perfusion chamber (RC-22, Warner Instruments, Hamden,
CT, USA) fitted with a microscope (Eclipse FN-1 Fixed Stage Microscope,
Nikon, Melville, NY, USA, Gibraltar Stage) and maintained under a flow
(2 mL/minute) of oxygenated bicarbonate buffer (126 mmol/L NaCl,
2.5 mmol/L KCl, 1 mmol/L NaH2PO4, 26 mmol/L NaHCO3, 1.2 mmol/L MgCl2,
2.4 mmol/L CaCl2, 11 mmol/L glucose) heated to 37 1C. For electrochemical
recordings, a carbon fiber electrode was lowered 75mm into the tissue
underneath the anterior commissure. A tungsten bipolar stimulating
electrode (Frederick Haer, Bowdoinham, ME, USA) was placed on the
surface of the slice proximal to the recording electrode.
Pharmacological Investigations
In the first set of experiments, pharmacological agents were introduced
systemically by intraperitoneal injection. First, a 30-minute baseline was
established by repeating a 60 pulse electrical stimulus every 5 minutes.
Next, sterile saline (1 mL) was administered as a vehicle control,
followed by a selective norepinephrine drug. These included idazoxan
(a2 antagonist, 5 mg/kg), desipramine HCl (transporter inhibitor, 15 mg/kg),
propranolol HCl (non-selective b-antagonist, 20 mg/kg), and terazosin
(a1 antagonist, 5 mg/kg, Tocris Bioscience, Bristol, UK). Doses were chosen
to identify receptor contributions, not to quantitatively assess their relative
effects. All drugs were dissolved in 0.5 mL saline, except for terazosin,
which was dissolved in 1.0 mL saline with gentle heat. Data were collected
for at least 45 minutes after drug administration to allow maximum effects.
A second set of experiments used iontophoresis to introduce the
adrenoceptor antagonists as well as N-nitro-L-arginine methyl ester
(L-NAME, nitric oxide (NO) synthase inhibitor) and 1-aminobenzotriazole
(cytochrome P450 inhibitor, Tocris Bioscience) directly at the recording
electrode. Iontophoresis solutions were prepared as 5 mmol/L drug,
5 mmol/L 4-methylcatechol, and 5 mmol/L NaCl, adjusted to pH 5.6.
4-methylcatechol provided an electroactive marker to monitor ejections
with fast-scan cyclic voltammetry.22 Drug concentrations were calculated
from the relative mobility of each pharmacological agent relative to
4-methylcatechol. Ejections were induced by positive current (5 to 400 nA)
generated by a constant current source (Neurophore, Harvard Apparatus,
Holliston, MA, USA). Each iontophoresis barrel was primed at a depth
dorsal to the vBNST ( 5 mm to  6 mm) to ensure reproducible ejection
profiles, and a negative retaining current ( 1 to 10 nA) was applied to any
leaking barrels. After baseline measurements were taken as described for
the intraperitoneal protocol, drugs were applied through a 30-second
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ejection. Ejection of 4-methylcatechol did not evoke O2 changes (vide infra)
and so it served as a control. Ejected drug concentrations were between 5
to 35 mmol/L at the carbon fiber. Measured ejections currents were allowed
to return to baseline before stimulation data were collected.
A third type of pharmacological manipulation involved local introduc-
tion of norepinephrine-selective agonists through iontophoresis. Drugs
were prepared as described for the antagonist ejections. Methoxamine
(a1agonist) and clonidine (a2 agonist) solutions contained 4-methylcate-
chol to monitor their ejections electrochemically. Norepinephrine and
isoproterenol (non-selective b-agonist) were prepared without 4-methyl-
catechol as both are electroactive. Each was ejected in the vBNST for
1 second (3 to 5 minutes apart) to reproduce the duration of the
electrical stimulation used in other portions of this study. Based on
the capabilities of the iontophoresis barrel, a range of concentrations
(between 1–20mmol/L) was tested for each agonist. For some experiments
antagonists were loaded into the remaining iontophoresis barrels. In these
experiments, baseline norepinephrine responses were recorded for
30 minutes before an antagonist was administered following the protocol
of the electrical stimulation experiments.
Signal Verification
The placement of the stimulating electrode also activates the dopaminer-
gic neurons of the ventral tegmental area.28 To ensure that the
voltammetric catecholamine signal was due to norepinephrine, and not
structurally-similar dopamine, each experiment ended with intraperitoneal
administration of raclopride (dopamine D2 autoreceptor antagonist)
followed by either idazoxan (a2 autoreceptor antagonist) or desipramine
(norepinephrine transporter inhibitor). Only locations that selectively
responded to the norepinephrine drugs were used in this study.28
Histology
At the end of data collection, a constant potential (10 V, 30 seconds) was
applied to the carbon fiber to lesion the recording site. Animals were then
killed with an overdose of urethane. Brains were promptly removed and
fixed with 10% formalin and post-fixed for at least three days before
coronal slices (40 to 50 mm) were prepared on a freezing microtome (Leica,
Wetzlar, Germany), mounted on a glass slide, coverslipped, and viewed
under a light microscope.
Locus Coeruleus Lesioning with DSP-4
The LC-selective neurotoxin DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromoben-
zylamine)29 was administered to rats (n¼ 5, 150 to 200 g) in two doses
(0.5 mL, 50 mg/kg, intraperitioneal) 3 days apart. DSP-4 was dissolved in
saline immediately before use. Measurements commenced 9 days after the
last dose to allow peripheral effects to diminish. Untreated rats were used
as a control in both experiments.
Immunohistochemistry
Rats were anaesthetized with urethane and transcardially perfused with
0.1 mol/L phosphate-buffered saline at pH 7.4, followed by 4% parafor-
maldehyde in phosphate-buffered saline. Brains were removed, post-fixed
for 424 hours, then cryoprotected in 30% sucrose for 448 hours. Sections
(40mm) were cut with a freezing microtome (Leica) and collected in
0.1 mol/L phosphate-buffered saline.
Immunofluorescence procedures were adapted from elsewhere.30
Briefly, sections were washed in 0.1 mol/L Tris-buffered saline (TBS), pH
7.4, then blocked with 5% normal donkey serum in TBS with 0.3% Triton
X-100 (NDS-TBS-T) for 1 hour. Tissue was incubated overnight at 4 1C in
primary cocktail prepared in NDS-TBS-T, which contained mouse anti glial
fibrillary acidic protein (1:300, Sigma), rabbit-anti-DBH (1:500, Immunostar,
Hudson, WI, USA), and biotinylated solanum tuberosum lectin (20mg/mL,
Vector). After 3 rinses in TBS-T, sections were incubated in secondary
cocktail for 2 hours at room temperature. Secondary cocktail was prepared in
TBS with 2% bovine serum albumin and contained AlexaFlour 488-
conjugated goat-anti-rabbit immunoglobulin G (1:500, Life Technologies,
Carlsbad, CA, USA), Alex Fluor 633-conjugated goat-anti-mouse immuno-
globulin G (1:500, Life Technologies), and streptavidin-DyLight 405 (20mg/mL,
Fisher, Pittsburgh, PA, USA). Sections were rinsed extensively in TBS, mounted
and coverslipped with Fluoromount (Sigma) before visualization on a
confocal microscope.
Sections were analyzed with a FV1000 microscope (Olympus, Tokyo,
Japan) equipped with a diode laser, argon laser, and helium-neon laser for
the excitations of DyLight 405, Alexa Fluor 488, and Alexa Fluor 633,
respectively. Images are based on a single optical section of o1 mm
thickness, and captured using FV1000ASW software (Olympus). DBH
quantification employed constant acquisition parameters and three
sections ( 0.05 mm to þ 0.05 mm anterior–posterior from bregma) were
analyzed for each animal. Mean pixel intensity was analyzed using image J
software in a 9000 square pixel area. For the vBNST, a rectangle of 450 by
200 pixels was drawn directly beneath the anterior commissure, and
cortical sections were analyzed in a 300 by 300 pixel square.
Cardiorespiratory Measurements
The cardiorespiratory effects of anesthesia and systemic adrenergic
antagonism were determined in a separate group of rats (300 to 400 g).
A MouseOx pulse oximeter system equipped with a collar sensor (Starr Life
Sciences, Oakmont, PA, USA) was used to monitor heart rate (beats per
minute) and respiratory rate (breaths per minute). Pre-urethane measure-
ments were taken with the animal at rest. Anesthetized data were
collected 3 hours after administration of urethane (1.5 g/kg). Thereafter,
one of four adrenergic antagonists (terazosin, idazoxan, propranolol or
desipramine) was delivered (intraperitioneal) at the dose listed under
Pharmacological Investigations. Post-drug cardiorespiratory values were
recorded 35 minutes after injection.
RESULTS
Immunohistochemistry of Recording Environment
Immunohistochemistry was employed to provide an overview of
the neurovascular environment of the vBNST on the spatial scale
of our recording electrode. Three major neurovascular compo-
nents were targeted: microvessels (STL), glial cells (glial fibrillary
acidic protein), and norepinephrine terminals (DBH). Their
distribution is shown in Figure 1. At these coordinates, the ventral
portion of the BNST is located underneath the anterior
commissure. A range of vessel sizes (B3 to 15 mm) were found
within the vBNST confirming the presence of both arterioles and
capillaries. Astrocytes were highly associated with the larger
microvessels as well as with the myelinated axon fibers compos-
ing the anterior commissure.
Consistent with our previous work,27 the densest region of
noradrenergic innervation was located within the vBNST. At
higher magnifications, these terminals appeared scattered within
the perivascular space in proximity to both microvessels and
astrocytes, as has been reported for cortical regions. Within the
areas of highest terminal density, spanning only B1 mm along the
medial–lateral plane, vascular heterogeneity is apparent. The
dimensions of the carbon fiber microelectrode (100 mm length,
5 mm diameter, superimposed in Figure 1E) are small enough to
probe these microenvironments. In these experiments, the
placement of the carbon fiber electrode was optimized for the
detection of norepinephrine, not for the detection of O2 changes.
Therefore, the immediate neurovascular landscape likely varied
between recording locations.
O2 Response with Electrical Stimulation
To investigate whether norepinephrine release in the vBNST
coincides with O2 changes, electrical stimulation of the VNB was
used to induce norepinephrine overflow while extracellular O2 and
norepinephrine changes were monitored simultaneously. Norepi-
nephrine has a peak oxidation potential of 0.75 V and a peak for
reduction of its electroformed o-quinone at  0.2 V on the
negative going scan. O2 is reduced at  1.35 V on the negative
going scan (Supplementary Figure 1). We found that O2 changes
accompanied VNB stimulation and that the responses were
variable between animals (Supplementary Figure 2). Minor
adjustment of the recording and stimulating electrode depths
did not have a significant effect on the measured O2 signal
(Supplementary Figure 3). This suggests signal variability may be a
result of anterior–posterior/medial–lateral positioning.
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One stimulated O2 response predominated in our studies
(B65% of locations) and thus was chosen for pharmacological
characterization. In this response, O2 levels rose after the
stimulation and reached a maximum (6.98±0.93 mmol/L) on
average 1.9±0.1 second after stimulation onset. This increase
was subsequently followed by a transient dip below baseline
concentrations ( 3.98±0.74 mmol/L), peaking 9.6±0.2 seconds
after the stimulation. We termed the initial O2 increase as event 1
and the subsequent decrease as event 2. In many animals a
second, prolonged increase in extracellular O2 was measured after
the initial response long after clearance of norepinephrine, similar
to our previous recordings in the striatum.25 The second O2
increase was unaffected by local adrenoceptor pharmacology
(Supplementary Figure 4). Thus, our discussion focuses on events
1 and 2.
Example data averaged over multiple trials from a single animal
are provided in Figure 2A. Multiple chemical fluctuations are
visible in the color plot. Immediately after the stimulation,
norepinephrine release is apparent as positive current at its
oxidation potential. Concurrent O2 fluctuations appear at  1.35 V
on the forward voltage scan. As O2 is detected through its
reduction, negative currents correspond to increases in concen-
tration, while positive currents indicate decreases. These O2 events
are accompanied by pH changes25 that overlap with the oxidation
potential of norepinephrine at later times in the recording. A
positive current feature occurs after the  1.4 V switching
potential during the stimulation. It is because of adsorption of
ions such as Ca2þ .31
The amplitude of each O2 event was compared with the
amount of released norepinephrine evoked by the electrical
stimulation. While both responses correlated with peak norepi-
nephrine concentration across animals, event 2 exhibited a better
linear fit (r2¼ 0.61) in comparison to event 1 (r2¼ 0.27). To vary
the amount of norepinephrine released in one location, the
duration of the electrical stimulation was varied (0.17 to
1.33 seconds) by changing the number of electrical pulses applied.
Norepinephrine release and the O2 changes increased linearly
with pulse number within this range. The response of event 1 to
stimulation duration was significantly different from that of
norepinephrine (Po0.01) and of event 2 (Po0.05). The pulse
dependence of event 2, however, closely resembled the norepine-
phrine response (P40.05).
We also examined the effects of electrically stimulated
norepinephrine release in a coronal brain slice that contained
the vBNST. The stimulation (60 pulses, 60 Hz) was evoked with a
bipolar electrode placed 100 to 200mm from the carbon fiber
electrode. After the stimulation, O2 decreased by 36.1±6.2 mmol/L
in a monotonic fashion, reaching a minima 17.9±3.1 second after
the stimulation (n¼ 3 animals, two slices from each animal).
Effect of DSP-4 on Electrically Stimulated O2 Response
To ascertain whether the stimulated O2 changes were dependent
on LC activity a subset of animals in this study was treated with
the neurotoxin DSP-4. DSP-4 causes selective degradation of LC
norepinephrine axons, leaving the norepinephrine neurons of the
brainstem nuclei intact.29 DSP-4 significantly reduced norepine-
phrine terminal density in the cortical region above the BNST
(Po0.001, n¼ 5), which receives its innervation solely from LC
neurons.29 DSP-4 did not, however, exert a significant effect on
the terminal density within vBNST (Supplementary Figure 5).
Responses to VNB stimulation also remained intact after DSP-4. In
treated animals, no significant differences in peak times and
magnitudes were found for norepinephrine release and the O2
response (Table 1).
O2 Response with Adrenoceptor Blockade
While electrical stimulation is an effective means to depolarize
proximal neurons, its effects are relatively non-selective, causing
release of other neuromodulators. We therefore employed
selective antagonists to determine the involvement of noradre-
nergic receptors in the electrically stimulated O2 response. Drugs
were introduced both systemically (intraperitoneal injection) and
locally at the recording site (iontophoresis ejection). Because
Figure 1. Confocal laser scanning images of triple-fluorescence labeling in the rat ventral bed nucleus of the stria terminalis (vBNST). (A) Lectin
staining of vasculature and microglia with biotinylated Solanum tuberosum agglutinin (STL) and DyLight 405 conjugated streptavidin, color
coded in green (AC, anterior commissure). Simultaneously labeled astroglia are shown in (B) with mouse anti-glial fibrillary acidic protein
(GFAP) and Alexa Fluor-633-tagged goat anti-mouse immunoglobulin G (IgG), color coded in red. Concomitantly revealed norepinephrine
terminals were color coded in blue, and visualized in (C) using rabbit anti-dopamine beta hydroxylase (DBH) and Alexa Fluor-488 goat anti-
rabbit IgG. (D) A merge of A, B, and C. An example of glial vessel colocalization is indicated by an asterisk and appears yellow. Terminal glial
colocalization is seen in pink. Scale bar, 200 mm. Insets demonstrate the triangle-labeled features at higher magnification. Scale bar, 50 mm. (E)
Further magnification in a different slice revealed the diverse architecture of blood vessels (arrow), microglia (open triangle), astrocytes
(chevron), and norepinephrine terminals (blue) within the vBNST. Sites where norepinephrine terminals interact with vessels and/or astroglia
are indicated by closed triangles. An electron micrograph of a 100 mm long carbon fiber microelectrode is superimposed to demonstrate the
electrochemical sampling environment. Scale bar, 20 mm.
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systemic administration of adrenergic drugs and anesthesia can
influence cardiorespiratory function, we also monitored heart rate
and breathing rate after their systemic application (Supplementary
Figure 6). Urethane had no effect on breathing rate but did
suppress heart rate. The adrenergic drugs exerted minor effects on
these parameters.
Pharmacology of the VNB-stimulated O2 changes is summarized
in Figure 3. The average baseline peak amplitudes of event 1 and
2 were taken as 100% and compared with post-drug values.
Vehicle treatments (local or systemic) did not affect either event.
Event 1 was only affected by systemic administration of terazosin,
an a1-antagonist, and local administration of L-NAME, a NO
synthesis inhibitor. Event 2 was attenuated by local administration
of 1-aminobenzotriazole, a cytochrome P450/20-HETE synthesis
inhibitor. Interestingly, event 2 was also sensitive to local blockade
of all adrenoceptor types, decreasing with administration of
terazosin, idazoxan (a2 antagonist), and propranolol (b-anta-
gonist). Systemic administration of the adrenergic drugs produced
matching results except for terazosin, probably because of its
competing effect on event 1. To assess the effect of increasing
stimulated norepinephrine release without influencing presynap-
tic a2 activity, which controls autoinhibition of release, the
norepinephrine transporter blocker desipramine was adminis-
tered. Desipramine increased the magnitude of event 2, although
the effect was only significant with systemic administration.
As this result opposes the effects of a2 inhibition, the effect of
idazoxan on the O2 response is most likely due to post-synaptic
actions, not increased norepinephrine overflow.
Table 1. Average responses to ventral noradrenergic bundle stimulation
Group Norepinephrine Event 1 Event 2
[NE]max (mmol/L) tmax (s) [O2]max (mmol/L) tmax (s) [O2]max (mmol/L) tmax (s)
Control 0.22±0.04 1.9±0.1 6.98±0.93 2.7±0.1  3.98±0.74 9.6±0.2
DSP-4 0.24±0.10 2.0±0.1 6.50±1.95 3.2±0.5  5.59±1.27 10.6±1.3
No statistical difference between control and DSP-4 treated animals, t-test with Welch’s correction for unequal variance. Control n¼ 25, DSP-4 treatment n¼ 5.
Figure 2. Predominant O2 response recorded in the ventral bed nucleus of the stria terminalis with electrical stimulation of the ventral
noradrenergic bundle. (A) Representative data averaged from 10 consecutive stimulations in a single animal. Current at all applied potentials
is visualized in a false color display (left) with the stimulation time denoted by the red bar. Extracellular O2 is monitored at its reduction
potential ( 1.35 V, I). Current extracted from this potential reveals a biphasic O2 response after electrical stimulation. Norepinephrine release
is simultaneously measured at its oxidation potential (þ 0.75 V, II) and is visible shortly after the stimulation onset. Changes in extracellular pH
also generate current at this potential later in the recording (asterisks). Dashed lines indicate the s.e.m. for these measurements. (B) Magnitude
of the O2 response compared with stimulated norepinephrine release across multiple animals (n¼ 25). Both O2 events showed linear
responses to the concentration of evoked norepinephrine (event 1: 11.46±3.90 mmol/L O2/mmol/L NE, r
2¼ 0.27; event 2:  14.20±2.37 mmol/L
O2/mmol/L NE, r
2¼ 0.61). (C) Average peak amplitudes for norepinephrine and O2 as a function of stimulation pulse number (n¼ 5, 10 to 80
pulses). Each data set is normalized to the 60 pulse response. Responses for O2 (event 1: r
2¼ 0.849; event 2: r2¼ 0.895) and norepinephrine
(r2¼ 0.997) were linear within this pulse range.
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Local Iontophoresis of Norepinephrine
To preclude the confounding effects of co-release with electrical
stimulation, we used iontophoresis to directly apply norepinephr-
ine at the site of the recording electrode within the vBNST
(Figure 4). Iontophoresis of 4-methylcatechol, the electroactive
marker for the drug solutions, did not produce current changes at
the reduction potential for O2 (Figure 4B), confirming the absence
of vehicle effects. Administration of norepinephrine (1 second
ejections), however, induced O2 fluctuations that mimicked those
following VNB stimulation (Figure 4C). When this experiment was
repeated in brain slice preparations, no O2 response was observed
with iontophoresis of norepinephrine (Figure 4D, n¼ 4 animals,
two slices from each animal).
Using the carbon fiber microelectrode to monitor iontophoretic
ejections, a range of norepinephrine concentrations (1 second
ejections) were delivered at each recording location. Both the
increase (event 1) and decrease (event 2) phases of the O2
response showed dose dependence to the amount of norepi-
nephrine ejected (Figure 4E). Neither event saturated within the
range of norepinephrine concentrations assayed (50 nmol/L to
15mmol/L). The absolute ratio of event 1 to event 2 (0.81±0.07,
n¼ 12 animals, 27 concentrations) was lower than for electrical
stimulation (4.87±1.52, n¼ 25 animals). As with electrical
stimulation, the peak time of event 1 closely tracked the ejection,
while the peak time of event 2 was more delayed with increased
norepinephrine output (tp¼ 11.2 to 23.2 seconds after ejection,
Supplementary Figure 7). There was some variability in the O2
response between animals. In a few locations (16.7%) only event 1
was evoked, while in others (16.7%) only event 2 was produced.
Local response pharmacology was investigated by using the
remaining iontophoresis barrels to apply norepinephrine receptor
antagonists. Event 1 was sensitive to b-receptor antagonism by
propranolol (Po0.05, n¼ 5). Similar to the VNB-stimulated
response, event 2 could be attenuated by inhibition of all receptor
types (Po0.01 for terazosin, n¼ 3, idazoxan, n¼ 4, and propra-
nolol, n¼ 5, Figure 4F).
Local Iontophoresis of Selective Adrenoceptor Agonists
Methoxamine (a1 agonist), clonidine (a2 agonist), and iso-
proterenol (b-agonist) were delivered iontophoretically (1 second
ejections, 1 to 15 mmol/L) to assess whether any portion of the O2
response could be triggered by activation of a single adrenoceptor
type. Example responses are provided in Figure 6. Agonism of a1
and a2 receptors induced transient O2 decreases (Figures 5A and
5B). The timing and number of these decreases varied from trial-
to-trial and across animals. In some animals, no response was
apparent while in others, the response was oscillatory in nature. In
contrast, the b-agonist isoproterenol produced a time-locked
increase in extracellular O2, which reached a maximum slightly
after the ejection. This response was found in all vBNST locations
assayed (Figure 5C). In many animals (63.6%), the O2 increase was
again followed by a transient decrease event (Figure 5C, right).
Compared with the responses observed after iontophoresis
of norepinephrine, the absolute ratio of event 1 to event 2 was
much larger for isoproterenol (5.40±0.87, n¼ 11 animals, 22
concentrations).
DISCUSSION
A vast collection of literature supports a role for noradrenergic
neurotransmission in functional hyperemia.10,32 The simultaneous
detection of norepinephrine and O2 with high temporal resolution
permitted us to directly probe local noradrenergic mechanisms.
Moreover, the micrometer dimensions of the carbon fiber
electrode allowed us to target the vBNST, a deep brain region
innervated by non-coerulean norepinephrine neurons. We found
both electrically evoked and iontophoretically applied norepine-
phrine induced similar O2 responses in this region. Norepine-
phrine was found to have opposing roles in these responses. The
initial O2 increase involved a b-component, but principally
originated from release of other substances including NO. At
later times, synergistic activation of a- and b-adrenoceptors
induced an O2 decrease. These results reveal the complex
control of O2 levels by norepinephrine in the vBNST that
originates from the multicellular locations of its receptors and
their modulation of other chemical messengers (Figure 6). In a
slice preparation, where blood flow is absent but metabolic
activity can be evoked, increasing O2 consumption, electrical
stimulation caused prolonged O2 decreases. O2 changes were not
detectable after iontophoresis of norepinephrine in slices. These
results support a hyperemic origin of the in vivo O2 responses.
The vasoactions of central norepinephrine are usually attributed
to LC neurons.5,8,10,15,32 In our preparation, the placement of the
stimulating electrode activates other noradrenergic neurons,
including the nucleus of the solitary tract and A1 cell groups.

























































Figure 3. Pharmacology of the ventral noradrenergic bundle-
stimulated O2 response recorded in the ventral bed nucleus of the
stria terminalis. The substrate inhibited is indicated underneath the
data columns. Systemic drug administration (solid) was performed
through intraperitoneal injection. Local drug administration (cross-
hatch) was accomplished through iontophoretic ejection. n¼ 5 for
all groups except saline (n¼ 25). Data are reported as a percentage
of baseline. Significance was determined by a one-way analysis
of variance with a Bonferroni post hoc test comparing drug
with its vehicle control (saline or 4-MC). *Po0.05, **Po0.01,
***Po0.001. ABT, 1-aminobenzotriazole; CYP, cytochrome P450;
DMI, desipramine; IDA, idazoxan; 4-MC, 4-methylcatechol; LN,
L-NAME; NET, norepinephrine transporter; NOS, nitric oxide
synthase; PROP, propranolol; TZ, terazosin.
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off-target depolarizations. As the vBNST receives a small
percentage of its noradrenergic innervation from the LC,33 and
electrical stimulation of the LC elicits release,27 we needed to
assess coerulean influence on O2 dynamics in the vBNST. To
achieve this, we lesioned LC fibers with a selective neurotoxin.
Electrically evoked O2 responses were unchanged after LC
lesioning, suggesting the noradrenergic contribution arose from
the nucleus of the solitary tract and A1 innervation, and not
indirect LC stimulation. As DSP-4 does affect hemodynamics in
cortical regions,15,32 it is unlikely that our results are skewed by
compensatory mechanisms that evolved between administration
of the neurotoxin and the recordings. To our knowledge, this data
is the first to implicate norepinephrine release from these
medullary cell populations in functional hyperemia.
Variation in O2 fluctuations was witnessed across animals, which
was likely due in part to the ability of our sensor to capture
neurovascular heterogeneity that exists at submillimeter scales
within the vBNST. However, in the majority of animals, electrical
stimulation evoked an O2 increase, which closely resembled the
temporal dynamics of norepinephrine release and uptake,
followed by an O2 decrease. We observed similar effects after
iontophoretic application of norepinephrine, affirming that
norepinephrine’s effects were mediated in the local terminal field
and not by activity in other brain regions. In both stimulation and
iontophoresis paradigms, the magnitude of each O2 event
increased with the norepinephrine output, but did not saturate
within the concentration ranges assayed. Taken together, these
data support the notion that norepinephrine release affects a
Figure 4. O2 changes induced by direct delivery of norepinephrine with iontophoresis. (A–D) Example responses from a single recording
location. Introduction of 4 mmol/L norepinephrine in vivo (C) evokes a biphasic O2 response that is not an artifact of natural activity (A) or
vehicle (B, ejection of 4 mmol/L 4-methylcatechol). Iontophoresis of similar norepinephrine concentrations in the ventral bed nucleus of the
stria terminalis in a brain slice does not induce O2 changes (D, 4 mmol/L ejection). The recording potential for O2 is indicated by the white
dashed lines. Ejection times (1 second in duration) are denoted by the red and gray dashed bars. (E) Magnitude of O2 changes compared
with the concentration of norepinephrine measured at the electrode. Data collected from the same recording location (average of 6 to 10
stimulations) are coded by point color and shape. (F) Effect of iontophoresed adrenoceptor antagonists terazosin (TZ, n¼ 3), idazoxan
(IDA, n¼ 4) and propranolol (PROP, n¼ 5)) on the O2 response. Significance was determined by a Dunnett’s post hoc test after a one-way
analysis of variance. *Po0.05, **Po0.01. IDA, idazoxan; PROP, propranolol; TZ, terazosin.
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vascular area proportional to presynaptic activity, consistent with
restricted volume neurotransmission.
Adrenoceptors are expressed in neurons, astrocytes, endothelial
cells, pericytes, and smooth muscle7,34—the major constituents of
the neurovascular system. Indeed, 8% of noradrenergic terminals
in the cortex are located in the perivascular space, and are not
proximal to neuronal targets.5 Through receptor activation,
norepinephrine likely influences the concerted actions of these
components to support metabolic needs. The data here
demonstrate that each event of the O2 response had distinct
signaling pathways. In the vBNST, we found event 1 to be partially
dependent on local b-receptor activity. When evoked by direct
application of norepinephrine, event 1 could be blocked by the
non-selective b-antagonist, propranolol, and was reproduced by
the b-agonist, isoproterenol. This pharmacology is consistent with
the well-documented dilatory effect of b-receptors on vascular
smooth muscle. As b-receptors are expressed on rat cerebral
microvessels,35 a transient surge of norepinephrine in the vBNST
may directly induce local vasodilation, thereby increasing the
inflow of O2-rich blood and giving rise to event 1. Indirect
mechanisms cannot be discounted, however. Stimulation of
b-receptors in this region may influence local cell activity and, in
turn, the release of vasodilators dependent on this activity. A study
by Winder and coworkers36 found b-pharmacology to have no
Figure 5. O2 changes induced by local delivery of adrenoceptor agonists with iontophoresis. Example responses to methoxamine (a1 agonist,
A), clonidine (a2 agonist, B), and isoproterenol (non-selective b-agonist, panel C) are shown for different recording locations. The recording
potential for O2 is indicated by the whited dashed lines. Ejection times (1 second in duration) are denoted by the gray dashed bars and the red
bars.
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effect on glutamatergic transmission in the vBNST. Therefore, if
event 1 is produced by an indirect noradrenergic mechanism, it is
unlikely due to the alteration of glutamatergic activity.
In apparent contradiction, electrically evoked O2 changes only
responded to peripheral blockade of a1 receptors. Adrenergic a1
receptors are known to constrict superficial cerebral arteries and
arterioles in the rat,32 and their dilation may blunt the redirection
of blood flow to the BNST. Consistent with a remote location
of a1 modulation, Event 1 was not produced or inhibited by
local application of a1 pharmacology. While iontophoresis of the
b-agonist produced an O2 increase, its contribution to event 1
appears to be masked when evoked through electrical
stimulation. This is likely because of the actions of co-released
neuromodulators initiated by non-selective neuronal activation.
Ventral noradrenergic bundle stimulation also depolarizes neurons
in the ventral tegmental area/substantia nigra that could release
vasodilators such as acetylcholine,25 which cannot be detected by
our technique. Consistent with this view, we found that event 1
could be attenuated by inhibiting the synthesis of NO locally in
the vBNST.
During the second O2 event, concentrations transiently
decreased below baseline levels. This observed decrease required
local activation of both a- and b-adrenoceptors. Although it is not
possible to comment on their relative contributions, inhibition of
each adrenoceptor attenuated the decrease. Interestingly, when
selective agonists were applied, only activation of b-receptors with
isoproterenol produced a time-locked response that resembled
event 2. In contrast, iontophoresis of the a-agonists methoxamine
and clonidine was followed by O2 decrease events. It is possible
that a1 and a2 receptors, which have higher affinity than b-types,
are partially occupied by tonic concentrations within the
norepinephrine-rich vBNST. Baseline a-activity therefore may be
enough to permit the O2 response when low affinity b-receptors
are stimulated. As expected in this scenario, the ratio of event 1 to
2 is much larger for isoproterenol in comparison with norepi-
nephrine, which binds to both a- and b-receptor types.
Although reported less frequently, cerebral O2 decreases have
been cited in the literature.37 For a healthy organism, it is unlikely
that these occurrences are due to an imbalance of metabolic
demand. More accepted are the theories that O2 decreases arise
from reduced blood flow because of either ‘vascular steal’ from
other activated brain regions or local neuronal inactivation. The
timing and pharmacology of event 2 in our study supports the
possibility of a constriction-mediated termination of the initial O2
increase, a function that has been associated with noradrenergic
signaling in the somatosensory cortex.32 Norepinephrine-
mediated constrictions are canonically produced by vascular
a-adrenoceptor activation. However, the b-sensitivity of event 2
and the temporal delay of its onset after norepinephrine clearance
indicate that the O2 decrease arises from noradrenergic activation
of other chemical messengers that subsequently act at the
vascular wall.
Astrocytes present a potential intermediary. These glial cells
express all adrenoceptor types and are well documented to
respond to norepinephrine.7,38 Of its many effects, noradrenergic
stimulation is reported to induce intracellular Ca2þ waves, which
can propagate over entire astrocyte populations. One study
demonstrated that norepinephrine-evoked Ca2þ events are
followed by constriction of nearby vessels, theorized to be due
to generation of 20-HETE.39 In agreement with their observations,
the magnitude of event 2 was reduced with 1-aminobenzotriazole,
which blocks formation of 20-HETE through inhibition of
cytochrome P450. In addition, we observed transient decreases
in O2 with a-adrenoceptor activation that were often oscillatory
in nature, much like astrocyte Ca2þ fluctuations. Supporting
the additional involvement of b-signaling in event 2, both
a- and b-receptors can stimulate astrocyte Ca2þ responses
in vivo,40,41 and synergistic activation of these receptors
potentiates Ca2þ responses in vitro.42 Although it is not possible
to dismiss indirect vascular effects through altered neuronal
activity,36 the reported effects of norepinephrine on astrocytes are
overall consistent with the temporal and pharmacological
characteristics of event 2.
In summary, we have established a role for brainstem
norepinephrine neurons in the control of extracellular O2 in a
terminal region. When activated, these cells increased norepi-
nephrine overflow in the vBNST, locally triggering a biphasic O2
response. This response was absent in a preparation that lacked
CBF and had distinct receptor mechanisms. The initial increase
involved a small b-receptor component and was also due to NO
formation. The subsequent decrease was induced by the
synergistic actions of a-and b-receptor types. The delayed
Figure 6. Proposed mechanism underlying the O2 responses
recorded after electrical stimulation of the ventral noradrenergic
bundle (VNB). Temporal (upper) and spatial (lower) models are
provided. Stimulation of the VNB induces norepinephrine release
from noradrenergic cells originating in the nucleus of the solitary
tract (NST) and A1 cell groups. Non-noradrenergic cell populations
coursing near the coordinates of the stimulating electrode are also
excited, leading to simultaneous release of other neurotransmitters
within the ventral bed nucleus of the stria terminalis (vBNST). This
overflow of norepinephrine and other vasoactive neurotransmitters
causes dilation of local microvessels and a subsequent influx of O2.
The noradrenergic contribution to this response is mediated
through activation of b-adrenoceptors either indirectly, by modulat-
ing local cell activity, or directly, by relaxation of vascular smooth
muscle. Local O2 concentrations continue to rise shortly after the
stimulation ceases. Thereafter, a signaling cascade initiated by the
synergistic activation of adrenoceptors on astrocytes results in the
release of secondary messengers from astrocytic endfeet. These
messengers act upon vessels to cause their constriction, and in turn,
provide an active termination of the hyperemic response. As a
result, O2 levels transiently decrease before returning to baseline
concentrations.
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temporal characteristics of this decrease indicate that adrenergic
activation induced a chemical cascade resulting in the formation
of 20-HETE, a known vasoconstrictor. Oscillatory O2 responses to
selective agonists suggest astrocytes may mediate this cascade.
These data support the view that norepinephrine is one of many
substances that can match energy demands and supply in the
brain.
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